TrialThe Lancet. Oncology2017

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Alexander E Perl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.